跳至主要内容
临床试验/NCT07327489
NCT07327489招募中不适用

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Elephas8 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2025年4月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
2,000
试验地点
8
主要终点
Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors & Researching Mechanisms of Tumor Cutting and Imaging

研究概览

简要总结

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

详细描述

Elephas is researching mechanisms of cutting, sorting and imaging tumors that leave the 3D tumor microenvironment (TME), including its immune cells, intact. This allows qualitative and semi-quantitative identification and characterization of the ex vivo response to exposure of potential immunotherapy. The ex vivo response data will then be compared to the clinical real world response data to inform development efforts.

This study will collect tumor specimens from patients with suspected or confirmed cancer. These specimens, along with clinical data and genomic data obtained as part of a patient's standard of care, will be used to perform this research.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Able and willing to provide informed consent for participation
  • Age ≥18 years at time of consent.
  • Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.
  • Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.

排除标准

  • Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.
  • Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.
  • Pregnant person(s).

研究组 & 干预措施

Study Population

Adults aged 18 years or older, who are able and willing to provide written informed consent, have a suspected or confirmed cancer diagnosis and will be undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up.

干预措施: Biopsy (Procedure)

结局指标

主要结局

Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors & Researching Mechanisms of Tumor Cutting and Imaging

时间窗: Study duration is approximately 36 months from enrollment to end of study.

Collect human tumor specimens to research mechanisms of tumor cutting, imaging, and ex-vivo immunotherapy treatment response, while maintaining cell stability in a live tumor microenvironment.

次要结局

未报告次要终点

研究者

发起方
Elephas
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Predicting Response to Immunotherapy From Analysis... | 临床试验